Tag: Anticoagulants

Stroke patients with normal, but not those with impaired, renal function have greater benefit with ticagrelor-aspirin than clopidogrel-aspirin

Risks for ischemic stroke or systemic embolism, bleeding reduced with apixaban versus rivaroxaban for atrial fibrillation and valvular heart disease

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Quality improvement effort tied to decrease in major bleeding without increase in thrombotic events

Two strong recommendations developed against use of heparin bridging in a-fib, and for continuation of VKA in patients getting pacemaker/ICD

However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy

Risk for adverse health outcomes higher for patients with Medicare Part D plans limiting access to non-vitamin K antagonist oral anticoagulants

Guideline addresses management of anticoagulants, antiplatelets during acute gastrointestinal bleeding and in the elective endoscopy setting

Recent use of non-vitamin K antagonist oral anticoagulant not linked to increased risk for intracranial hemorrhage with IV alteplase

Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin